Humacyte, Inc. (HUMA)
Humacyte, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.
Humacyte, Inc. (HUMA) is a Biotechnology company based in US with a market capitalization of $222.6M. Free cash flow was negative at -$105.9M. This page tracks HUMA's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.
US · 218 employees · IPO Dec 1, 2020
Valuation
Valuation & price
$0.93as of May 17, 2026· -65.9% vs 52w high
—
P/E ratio
Latest-FY diluted EPS
71.59
P/B ratio
Market cap ÷ book equity
—
Dividend yield
Price — last 12 months
Fundamentals
Key fundamentals
$222.6M
Market cap
—
Revenue growth (YoY)
-736.5%
Gross margin
-$105.9M
Free cash flow (USD)
$14.3M
Net debt
33.5%
Share dilution
0/5
Graham criteria passed
Defensive-investor screen
Healthcare
Sector
Trajectory
Long-term trends
Revenue by year
2019 → 2025
Free cash flow by year
2019 → 2025
Gross margin by year
2021 → 2025
Value screen
Graham defensive-investor tests
2
Insider buys · 90 days
2
Insider sells · 90 days
Earnings
Last report: 10-Q filed May 13, 2026
Next expected: not yet scheduled
On the tape
Recent SEC & insider activity
- 8-K eventJun 11, 2026Filing
Stock Offering
- 8-K eventJun 10, 2026Filing
Clinical Trial Results
- 8-K eventJun 9, 2026Filing
Authorized Shares Increase
- 8-K eventJun 5, 2026Filing
Regained Compliance
- Insider sellMay 20, 2026Filing
Insider Sell $41K · 10b5-1 PlanParikh Shamik J · Chief Medical Officer · $41.1K
- Insider sellMay 20, 2026Filing
Insider Sell $41K · 10b5-1 PlanSander Dale A. · CFO and Chief Corp. Dev. Off · $41.1K
- Insider buyMay 20, 2026Filing
Insider Buy $10KConstantino Michael T. · Director · $9.8K
- Insider buyMay 20, 2026Filing
Insider Buy $50KSebelius Kathleen · Director · $50K
- Quarterly reportMay 13, 2026Filing
10-Q Filed
- 8-K eventMay 8, 2026Filing
Delisting Notice
Questions
Frequently asked questions
What is Humacyte, Inc.'s market cap?
Humacyte, Inc. (HUMA) has a market capitalization of $222.6M.
What is HUMA's P/E ratio?
A meaningful P/E ratio is not available for HUMA — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.
What is HUMA's price-to-book (P/B) ratio?
HUMA trades at 71.59 times book value per share.
Are insiders buying HUMA stock?
Yes — SEC Form 4 filings show 2 open-market insider buys and 2 sells at Humacyte, Inc. in the last 90 days.
Same arena
Related companies in Biotechnology
Timeline
Every filing, insider trade & earnings on a price-anchored timeline
Filing Analyzer
Search the actual 10-K / 10-Q text with AI research angles
News
Latest press coverage in one feed
Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.